Magenta Therapeutics Inc Forecast, price target & analysts
Magenta Therapeutics Inc Target price 2025 - Analyst rating & recommendation
Magenta Therapeutics Inc Classifications & Recommendation:
Magenta Therapeutics Inc Price Target
| Target Price | $66.30 |
| Price | $40.85 |
| Potential |
62.30%
register free of charge
|
| Number of Estimates | 13 |
|
13 Analysts have issued a price target Magenta Therapeutics Inc 2026 .
The average Magenta Therapeutics Inc target price is $66.30.
This is
62.30%
register free of charge
$105.00
157.04%
register free of charge
$40.40
1.10%
register free of charge
|
|
| A rating was issued by 20 analysts: 19 Analysts recommend Magenta Therapeutics Inc to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Magenta Therapeutics Inc stock has an average upside potential 2026 of
62.30%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 6.24 | 2.32 |
| 120.49% | 62.80% | |
| Net Margin | -1,361.70% | -6,346.08% |
| 11.53% | 366.04% |
14 Analysts have issued a sales forecast Magenta Therapeutics Inc 2025 . The average Magenta Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
16 Magenta Therapeutics Inc Analysts have issued a net profit forecast 2025. The average Magenta Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.55 | -3.44 |
| 69.82% | 34.90% | |
| P/E | negative | |
| EV/Sales | 581.16 |
16 Analysts have issued a Magenta Therapeutics Inc forecast for earnings per share. The average Magenta Therapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Magenta Therapeutics Inc...
Current Magenta Therapeutics Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 10 2025 |
| Wedbush |
Locked
➜
Locked
|
Locked | Nov 06 2025 |
| Truist Securities |
Locked
➜
Locked
|
Locked | Oct 14 2025 |
| Clear Street |
Locked
➜
Locked
|
Locked | Sep 17 2025 |
| Stifel |
Locked
➜
Locked
|
Locked | Sep 12 2025 |
| Wedbush |
Locked
➜
Locked
|
Locked | Sep 12 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Sep 09 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 10 2025 |
|
Locked
Wedbush:
Locked
➜
Locked
|
Nov 06 2025 |
|
Locked
Truist Securities:
Locked
➜
Locked
|
Oct 14 2025 |
|
Locked
Clear Street:
Locked
➜
Locked
|
Sep 17 2025 |
|
Locked
Stifel:
Locked
➜
Locked
|
Sep 12 2025 |
|
Locked
Wedbush:
Locked
➜
Locked
|
Sep 12 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Sep 09 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
